The Goldman Sachs Group Cuts Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target to $43.00

Day One Biopharmaceuticals (NASDAQ:DAWN) had its price target lowered by The Goldman Sachs Group from $48.00 to $43.00 in a research note published on Monday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Several other research analysts also recently weighed in on DAWN. HC Wainwright reissued a “buy” rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. Needham & Company LLC reiterated a “buy” rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a research report on Monday, January 13th. Bank of America reduced their target price on Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Finally, TD Cowen upgraded Day One Biopharmaceuticals to a “strong-buy” rating in a report on Monday, November 4th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Day One Biopharmaceuticals currently has a consensus rating of “Buy” and an average price target of $35.71.

Day One Biopharmaceuticals Stock Up 1.8 %

Shares of Day One Biopharmaceuticals stock opened at $12.13 on Monday. Day One Biopharmaceuticals has a 12-month low of $11.13 and a 12-month high of $18.07. The firm has a market capitalization of $1.22 billion, a PE ratio of -11.78 and a beta of -1.46. The stock’s fifty day moving average is $12.52 and its 200-day moving average is $13.57.

Insider Activity at Day One Biopharmaceuticals

In related news, insider Samuel C. Blackman sold 30,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $13.31, for a total transaction of $399,300.00. Following the transaction, the insider now owns 1,034,015 shares of the company’s stock, valued at approximately $13,762,739.65. This trade represents a 2.82 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 8.40% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. ExodusPoint Capital Management LP bought a new stake in Day One Biopharmaceuticals in the fourth quarter worth $2,726,000. Trexquant Investment LP acquired a new stake in shares of Day One Biopharmaceuticals in the fourth quarter worth about $1,115,000. Geode Capital Management LLC boosted its stake in shares of Day One Biopharmaceuticals by 2.1% during the 4th quarter. Geode Capital Management LLC now owns 1,462,982 shares of the company’s stock worth $18,541,000 after acquiring an additional 30,285 shares in the last quarter. Franklin Resources Inc. boosted its stake in shares of Day One Biopharmaceuticals by 0.3% during the 4th quarter. Franklin Resources Inc. now owns 3,882,952 shares of the company’s stock worth $49,197,000 after acquiring an additional 13,320 shares in the last quarter. Finally, Wellington Management Group LLP increased its holdings in shares of Day One Biopharmaceuticals by 1.3% during the 4th quarter. Wellington Management Group LLP now owns 731,303 shares of the company’s stock valued at $9,266,000 after acquiring an additional 9,722 shares during the last quarter. Institutional investors and hedge funds own 87.95% of the company’s stock.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.